Role of the CD47 Pathway in Rheumatoid Arthritis
Official title: Role of the CD47 Pathway in Rheumatoid Arthritis Pathogenesis and Treatment
Funded at University of Rochester · NIH-11374511 · Data updated 2026-11-12
A study to understand how the CD47 pathway affects rheumatoid arthritis and whether blocking CD47 can improve joint inflammation and bone damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 20, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $480,269 |
| NIH project number | 5R01AR080015-05 |
| Project ID | NIH-11374511 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with rheumatoid arthritis whose disease biology involves CD47 signaling may benefit from future therapies explored in this program.
✕Less likely to help
People whose RA does not involve CD47-related pathways or who are not eligible for targeted biologics may not benefit.
What this research studies
This project will explore how CD47 signaling influences immune and tissue cells in rheumatoid arthritis using patient tissue, single-cell RNA data, and lab-grown joint models. It will also test arthritis outcomes in mice lacking CD47 and examine if combining anti-CD47 therapy with existing biologics provides better control of disease. The team plans to screen potential CD47-blocking treatments in the lab and then evaluate the most promising options in animal models. The goal is to identify new therapeutic approaches that could reduce inflammation and prevent bone erosion in people with RA.
Why it matters
Potential benefit: If successful, the work could lead to new combination therapies that better control RA and protect joints.
How similar studies have gone: Previous research suggests CD47 can influence immune and tissue cell behavior, but translating this to RA therapies is still being explored.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Korman, Benjamin Douglas — University of Rochester
- Study coordinator: Korman, Benjamin Douglas
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Role of Stabilin receptors in rheumatoid arthritis
A short study to understand how certain scavenger receptors may influence the development and progression of rheumatoid arthritis in adults.
-
IgG glycosylation and endothelial FcγRIIB: understanding RA-related heart and blood vessel disease
This project looks at how rheumatoid arthritis affects blood vessels and clotting, with the goal of uncovering new ways to prevent heart and stroke risk for people with RA.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Pregnancy changes in rheumatoid arthritis and new treatment ideas
This research seeks to understand why some women’s rheumatoid arthritis improves during pregnancy and how to predict and mimic that effect to make treatments safer and more effective for pregnant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.